Background: Solid organ transplant recipients taking immunosuppressive drugs are at greater risk of severe COVID-19 than the general population. In particular, kidney transplant recipients (KTRs) are known to have lower seropositivity after basal doses of SARS-CoV-2 vaccines, and the strategy of administering booster doses in these immunocompromised individuals has been promoted worldwide.
Methods: This study evaluated the effect of a fourth dose (D4) of SARS-CoV-2 vaccine in Japanese KTRs. Anti-spike (anti-S) IgG antibody titers at 1 and 3 months after D4 of SARS-CoV-2 vaccine were evaluated in 75 KTRs.
Results: The median anti-S IgG antibody titers at 1 and 3 months after D4 were 4728.1 (interquartile range [IQR]: 643.2-13,953.1) AU/mL and 3778 (IQR: 642-9436.6) AU/mL, respectively. The seropositivity rate after D4 was 85.1% at 1 month and 83.1% at 3 months, and the seroconversion rate was 28.6% (4 of 14 KTRs seronegative after the third dose). Factors associated with poor humoral responses were shorter time post-transplant to infection, a higher mycophenolate mofetil dose, a lower lymphocyte count, and a lower estimated glomerular filtration rate.
Conclusion: This study demonstrates some efficacy of D4 of SARS-CoV-2 vaccine in KTRs who are seronegative after three doses and encourages consideration of further booster doses of the SARS-CoV-2 vaccine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10157-025-02651-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Better Together: Implementation of a Public Health Learning Community During the COVID-19 Pandemic.
Am J Public Health
April 2025
Kristen M. Brown, Brigette Courtot, Zara Porter, and Sofia Hinojosa are with the Health Policy Center, Urban Institute, Washington, DC.
The Centers for Disease Control and Prevention's Partnering for Vaccine Equity program was developed during the COVID-19 public health emergency to fund more than 500 community-based organizations working to improve vaccine equity. Organizations were supported by a virtual learning community where members received tailored learning content, peer-to-peer learning opportunities, and resources that facilitated deployment of vaccine-related programming during a dynamic pandemic. Process evaluation metrics indicate successful implementation of the learning community.
View Article and Find Full Text PDFPrevalence and pattern of adverse events following COVID-19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria.
PLoS One
March 2025
Department of Pharmacology and Therapeutics, Usmanu Danfodiyo University, Sokoto, Nigeria.
Background: COVID-19 still poses a major public health challenge worldwide and vaccination remains one of the major interventions to control the disease. Different types of vaccines approved by the World Health Organization (WHO) are currently in use across the world to protect against the disease. This study assessed the prevalence and pattern of adverse events following immunization (AEFI) after receiving COVID-19 vaccine (the Oxford-AstraZeneca vaccine) among the adult population in Sokoto metropolis, North-west, Nigeria.
View Article and Find Full Text PDFRapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies.
J Immunol
February 2025
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Several vaccines and immunization strategies, including inactivated vaccines, have proven effective in eliciting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), providing an opportunity to characterize the antibody response. In this study, we investigated the monoclonal antibody responses elicited by wild-type SARS-CoV-2 inactivated vaccination compared to those elicited by natural infection and mRNA vaccination. The analysis showed that antibodies encoded by biased germline genes were shared between SARS-CoV-2 vaccinated and naturally infected individuals.
View Article and Find Full Text PDFEstimation and Hypothesis Testing of Strain-Specific Vaccine Efficacy With Missing Strain Types With Application to a COVID-19 Vaccine Trial.
Stat Med
March 2025
Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Based on data from a randomized, controlled vaccine efficacy trial, this article develops statistical methods for assessing vaccine efficacy (VE) to prevent COVID-19 infections by a discrete set of genetic strains of SARS-CoV-2. Strain-specific VE adjusting for possibly time-varying covariates is estimated using augmented inverse probability weighting to address missing viral genotypes under a competing risks model that allows separate baseline hazards for different risk groups. Hypothesis tests are developed to assess whether the vaccine provides at least a specified level of VE against some viral genotypes and whether VE varies across genotypes.
View Article and Find Full Text PDFVaccine Effectiveness Dynamics against Influenza and SARS-CoV-2 in Community-tested Patients in France 2023-2024.
Emerg Microbes Infect
March 2025
Hospices Civils de Lyon (HCL), Centre National des virus des infections respiratoires, Institut des Agents Infectieux, Laboratoire de Virologie, Lyon, France.
Background: The epidemiology of respiratory viruses and vaccine effectiveness (VE) in the community is not well described. This study assessed VE against a positive test of influenza (VEf) and SARS-CoV-2 (VECov).
Methods: Data from two large networks of community-based laboratories in France were collected during standard of care in the 2023-2024 epidemic season (n = 511,083 RT-PCR tests).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!